The Dow Chemical Company (NYSE:DOW) and Koehler Paper Group are the recipients of a 2017 U.S. Environmental Protection Agency (EPA) Presidential Green Chemistry Challenge Award. The award was given in the design of greener chemicals category for the development of ROPAQUE™ NT-2900 Opaque Polymer for BLUE 4EST™ Thermal Paper. This is the 11th Presidential Green Chemistry Award Dow and its affiliates have received since the EPA introduced the award in 1996. “BLUE 4EST™ Thermal Paper is an amazing innovation. It takes an entirely new approach, eliminates chemical developers for improved safety, yet still works in existing equipment,” said A.N. Sreeram, senior vice president, Research & Development, and chief technology officer for Dow. “It demonstrates the passion of our people to deliver inventive solutions to customer problems. The fact that Dow has earned more of these awards than any other company speaks to our focus on providing innovative products in a responsible way and our drive to collaborate with customers like Koehler to address growing consumer and regulatory demands.”
On Monday The Dow Chemical Company (NYSE:DOW) share price closed at $64.01. Company net profit margin stands at 9.20% whereas its return on equity (ROE) is 18.10%. The Dow Chemical Company (NYSE:DOW) is -2.16% away from its 52 week high.
TAL Education Group (NYSE:TAL) traded 778356 shares and its share price moved up 0.14% to close at $121.57. Company has 83.90% insider ownership. TAL Education Group (NYSE:TAL) quarterly performance is 30.75% while its year to date (YTD) performance is 74.00%.
On Monday shares of Bed Bath & Beyond Inc. (NASDAQ:BBBY) ended up at $36.49. This year Company’s Earnings per Share (EPS) growth is -10.30% and next year’s EPS growth is 0.63%. Beta of Bed Bath & Beyond Inc. (NASDAQ:BBBY) is 1.11 while company weekly performance is 4.74%.
Baxter International Inc (NYSE:BAX) highlighted new data on its novel HDx therapy enabled by the THERANOVA dialyzer at the 54th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA), June 3-6. Data from two independent studies concluded that HDx, or expanded hemodialysis therapy, enabled by the THERANOVA dialyzer effectively removed small and mid-sized toxins at similar rates when compared to hemodiafiltration (HDF), another type of dialysis. HDx therapy extends the range of molecules that can be filtered from the blood during dialysis, resulting in a filtration profile that more closely mimics the natural kidney.1 In addition to its clearance profile, HDx enabled by THERANOVA is as simple to perform as conventional hemodialysis (HD) and was designed to work with all HD machines. This allows clinics to offer HDx therapy using existing resources, and eliminates the need for special equipment and added clinic workflow, which is required for HDF. Additionally, HDF cannot be performed effectively for all patients.2
Baxter International Inc. (NYSE:BAX) decreased -2.99% to close at $57.15 on 12 June. Its return on assets (ROA) is 11.80% while return on investment (ROI) is 5.30%. Baxter International Inc. (NYSE:BAX) price to sales (P/S) ratio is 3.02.